CIA
MNTA

Capital Impact Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Capital Impact Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-12,026
Closed -$145K – 319
2014
Q4 		$145K Hold
12,026
– – 0.07% 180
2014
Q3 		$136 Hold
12,026
– – ﹤0.01% 169
2014
Q2 		$145K Buy
+12,026
New +$142K 0.11% 206

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Impact Advisors's MNTA Position: Q1 2015 in Review

Capital Impact Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2015, closing a stake of 12,026 shares — an estimated $145K sold.

Capital Impact Advisors first reported a position in MNTA in Q2 2014 and held it in 3 quarters. The position peaked at $145K in Q4 2014. 143 funds tracked by Wall St. Rank hold MNTA as of Q1 2015.

  • Capital Impact Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 12,026 Momenta Pharmaceuticals, Inc. shares in Q1 2015, an estimated $145K.
  • Capital Impact Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2014 and held it in 3 quarters.
  • Capital Impact Advisors's Momenta Pharmaceuticals, Inc. position peaked at $145K in Q4 2014.
  • 143 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2015.

Based on Capital Impact Advisors's 13F filing for Q1 2015, filed 29 May 2015.